NetworkNewsBreaks – Pressure BioSciences Inc. (P
Post# of 1354
Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform technology solutions to the worldwide life sciences and other key industries, today announced continued strong financial results for the second quarter ended June 30, 2021. In addition, the company provided a business update and offered guidance for the remainder of FY 2021. Among the highlights, the company reported a 127% increase in total revenue for Q2 2021 to $608,900 compared to $268,200 for Q2 2020, as well as a 178% increase in instrument sales to $337,400 compared to $121,400 for Q2 2020. “We are delighted to have followed our strong first quarter results with even stronger results in the second quarter,” said PBI’s Director of Sales and Marketing John B. Hollister. “Requests for instrument systems have increased significantly since the beginning of the year, purchases of consumable products started to pick up appreciably near the end of the second quarter, and interest in our BaroFold services has leaped forward into exciting new growth opportunities. In particular, we are pleased to report that demand for our pressure-based instruments and services continued to strengthen throughout the quarter and the year-to-date. We are looking forward to a busy and highly successful second half of 2021.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer